探讨机器人肝脏肿瘤切除日间手术的安全性与可行性。

回顾性分析2024年6月至2025年1月期间于中国人民解放军总医院第一医学中心肝胆胰外科医学部接受机器人肝脏肿瘤切除日间手术的患者的人口统计学特征、围手术期资料及短期结局。

共纳入31例患者(男性23例，女性8例)，平均年龄54岁。其中8例接受左外叶肝切除术，18例接受肝楔形切除术，5例接受肝段切除术。所有机器人肝脏肿瘤切除日间手术均顺利完成，无中转开腹病例。中位手术时间为100 (85.5，115.5) min，中位估计出血量为25(20，50)ml。无患者需要输血，无患者出现严重术后并发症、肝切除术后肝功能衰竭及肝切除术后出血。无患者需要再次手术或再入院，未观察到30 d死亡率。

机器人肝脏肿瘤切除日间手术是安全、可行的，但仍待进一步经验积累和对比研究论证其临床价值，明确手术适应证。

To explore the safety and feasibility of day surgery for robotic liver tumor resection.

The demographic characteristics, perioperative data, and short-term outcomes of patients who underwent robotic day surgery for liver tumor resection at Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People′s Liberation Army General Hospital from Jun.2024 to Jan.2025, were analyzed retrospectively.

A total of 31 patients were enrolled, including 23 males and 8 females, with a mean age of 54 years. Among them, 8 patients underwent left lateral hepatectomy, 18 underwent wedge hepatectomy, and 5 underwent segmentectomy. All day surgeries for robotic liver tumor resection were successfully completed without conversion to open surgery. The median operative time was 100 (85.5, 115.5) minutes, and the median estimated blood loss was 25 (20, 50) ml. No patient required blood transfusion, and no patient developed major postoperative complications, post-hepatectomy liver failure or post-hepatectomy hemorrhage. No patient needed reoperation or readmission, and no 30-day mortality was observed.

Day surgery for robotic liver tumor resection is safe and feasible. However, further accumulation of experience and comparative studies are required to verify its clinical value and clarify the surgical indications.